Ambria Dermatology

Ambria Dermatology is a clinical-stage biotechnology company focused on developing innovative topical therapies for inflammatory skin diseases. The company's lead program is a novel, potent, and selective Janus kinase (JAK) inhibitor designed for topical application to treat conditions such as atopic dermatitis and psoriasis. By utilizing a targeted delivery approach, Ambria aims to provide the efficacy of systemic JAK inhibitors while minimizing the safety concerns associated with oral administration. The company is led by a team of experienced dermatology drug developers and is currently advancing its pipeline through mid-stage clinical trials.